[{"id":"36d05294-4a12-477b-b97b-7d1705c42e3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03073525","created_at":"2021-01-18T15:08:28.985Z","updated_at":"2024-07-02T16:35:51.417Z","phase":"Phase 2","brief_title":"A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers","source_id_and_acronym":"NCT03073525","lead_sponsor":"Gradalis, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 05/18/2022","study_completion_date":" 05/18/2022","last_update_posted":"2023-04-05"},{"id":"71ce3557-7186-4552-8aeb-83c3fb94cbdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01061840","created_at":"2021-01-18T04:10:59.745Z","updated_at":"2024-07-02T16:36:15.390Z","phase":"Phase 1","brief_title":"Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer","source_id_and_acronym":"NCT01061840","lead_sponsor":"Gradalis, Inc.","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 12/06/2018","primary_completion_date":" 12/06/2018","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2022-03-15"},{"id":"79d3aa36-b552-432f-b11b-b6963dede275","acronym":"","url":"https://clinicaltrials.gov/study/NCT02725489","created_at":"2021-06-23T19:53:40.049Z","updated_at":"2025-02-25T14:57:37.030Z","phase":"Phase 2","brief_title":"Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers","source_id_and_acronym":"NCT02725489","lead_sponsor":"Mary Crowley Medical Research Center","biomarkers":" IFNG","pipe":" | ","alterations":" PD-L1 expression","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/03/2016","start_date":" 06/03/2016","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 12/02/2020","study_completion_date":" 12/02/2020","last_update_posted":"2021-01-27"},{"id":"8b173a76-6028-4f1a-b970-8488f8a9484f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02574533","created_at":"2021-01-18T12:28:37.846Z","updated_at":"2024-07-02T16:37:17.532Z","phase":"Phase 1","brief_title":"Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma","source_id_and_acronym":"NCT02574533","lead_sponsor":"Gradalis, Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2017-09-27"},{"id":"ff91548c-5e82-427d-8185-38552da3a2a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02639234","created_at":"2021-01-18T12:50:16.993Z","updated_at":"2024-07-02T16:37:19.356Z","phase":"Phase 2","brief_title":"Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02639234","lead_sponsor":"Gradalis, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Vigil (gemogenovatucel-T)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2017","primary_completion_date":" 03/01/2017","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2017-07-31"}]